Millennium Management
EWTX icon

Millennium Management’s Edgewise Therapeutics EWTX Stock Holding History

Millennium Management’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-70,000
Closed -$1.87M – 6083
2024
Q3 		$1.87M Buy
+70,000
New +$1.39M ﹤0.01% 3763

Other funds holding EWTX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Millennium Management's EWTX Position: Q1 2026 in Review

Millennium Management increased its Edgewise Therapeutics (EWTX) stake by 171% in Q1 2026, buying an estimated $6.24M and bringing the position to 342,867 shares worth $10.8M. The position accounts for ﹤0.01% of the portfolio, ranked #2100.

Millennium Management first reported a position in EWTX in Q1 2021 and has held it in 16 quarters since. The position peaked at $26.3M in Q3 2024. 214 funds tracked by Wall St. Rank hold EWTX as of Q1 2026.

  • Millennium Management held 342,867 shares of Edgewise Therapeutics worth $10.8M as of Q1 2026.
  • Millennium Management bought 216,431 Edgewise Therapeutics shares in Q1 2026, an estimated $6.24M.
  • Edgewise Therapeutics made up ﹤0.01% of Millennium Management's portfolio in Q1 2026, its #2100 holding.
  • Millennium Management first reported a position in Edgewise Therapeutics in Q1 2021 and has held it in 16 quarters since.
  • Millennium Management's Edgewise Therapeutics position peaked at $26.3M in Q3 2024.
  • 214 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.